- Home
- ISRL vs IKT Comparison
ISRL vs IKT Comparison
Compare ISRL & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- IKT
- Stock Information
- Founded
- ISRL 2021
- IKT 2008
- Country
- ISRL United States
- IKT United States
- Employees
- ISRL N/A
- IKT N/A
- Industry
- ISRL Blank Checks
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- IKT Health Care
- Exchange
- ISRL Nasdaq
- IKT Nasdaq
- Market Cap
- ISRL 145.6M
- IKT 159.2M
- IPO Year
- ISRL 2023
- IKT 2020
- Fundamental
- Price
- ISRL $11.36
- IKT $2.72
- Analyst Decision
- ISRL
- IKT Strong Buy
- Analyst Count
- ISRL 0
- IKT 2
- Target Price
- ISRL N/A
- IKT $6.50
- AVG Volume (30 Days)
- ISRL 35.6K
- IKT 288.1K
- Earning Date
- ISRL 01-01-0001
- IKT 11-14-2024
- Dividend Yield
- ISRL N/A
- IKT N/A
- EPS Growth
- ISRL N/A
- IKT N/A
- EPS
- ISRL 0.26
- IKT N/A
- Revenue
- ISRL N/A
- IKT $1.00
- Revenue This Year
- ISRL N/A
- IKT N/A
- Revenue Next Year
- ISRL N/A
- IKT N/A
- P/E Ratio
- ISRL $43.53
- IKT N/A
- Revenue Growth
- ISRL N/A
- IKT N/A
- 52 Week Low
- ISRL $10.69
- IKT $1.12
- 52 Week High
- ISRL $11.50
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ISRL 51.41
- IKT 41.71
- Support Level
- ISRL $11.30
- IKT $2.55
- Resistance Level
- ISRL $11.50
- IKT $2.90
- Average True Range (ATR)
- ISRL 0.02
- IKT 0.29
- MACD
- ISRL 0.00
- IKT -0.08
- Stochastic Oscillator
- ISRL 30.00
- IKT 18.09
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.